

## POSTER 100

### SMAD-SIGNALING INHIBITION: POTENTIAL FOR DEVELOPING NEWER TREATMENTS FOR CORNEAL FIBROSIS

Rangan Gupta PhD (Postdoctoral Fellow)

Ashish Tandon, PhD

Jonathan C.K. Tovey, MD

Ajay Sharma, PhD

(Rajiv R. Mohan, PhD)

University of Missouri Department of Ophthalmology  
Harry S Truman Veterans Memorial Hospital

**Purpose:** Transforming growth factor  $\beta$  (TGF $\beta$ ) is known to cause fibrosis in the cornea following injury and/or infection. Effective reduction in corneal fibrosis has been reported by inhibiting TGF $\beta$  activity. However, associated molecular mechanism is still unknown. The aim of study was to test the hypothesis that the alteration in SMAD signaling is a novel approach for treating corneal fibrosis using an established *in vitro* model.

**Methods:** Primary corneal fibroblast (HSF) cultures generated from donor human corneas were exposed to TGF $\beta$ 1 (1ng/ml). To test the hypothesis gene transfer approach was used. Decorin (a natural inhibitor of TGF $\beta$ ) cDNA was introduced into HSF with non-viral (lipids) or viral (AAV5) vector. Real-time PCR, immunoblotting and/or immunocytochemistry measured the markers of fibrosis ( $\alpha$ SMA, F-actin and fibronectin). Immunoblotting and/or immunocytochemistry examined the non-phosphorylated and phosphorylated forms of SMAD2 and SMAD7 proteins.

**Results:** TGF $\beta$ 1 treatment significantly induced myfibroblast formation and fibrosis in the HSF as shown by mRNA and protein levels of  $\alpha$ SMA (myfibroblasts marker). Decorin-transfected HSF showed significant decrease in TGF $\beta$ 1-induced fibrosis in the human cornea *in vitro*. Detection of significant increase in Smad7 and decrease in Smad2 levels in decorin-overexpressing clones was detected compared to naked vector-transfected clones. The effects were more pronounced in AAV-transduced clones than the plasmid-transfected clones, most likely due to the higher transgene delivery with AAV than the plasmid vector.

**Conclusions:** Inhibition of SMAD signaling pathway can be used for developing mechanism-based newer anti-fibrotic therapies for the cornea.